News | May 31, 2021
Margins impacted by high expenses for Pfizer: ICICI Securities
Adjusted PAT declined 18.8% YoY
Adjusted PAT declined 18.8% YoY
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
Subscribe To Our Newsletter & Stay Updated
